HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer

Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 113; no. 26; pp. E3735 - E3744
Main Authors Mahara, Sylvia, Lee, Puay Leng, Feng, Min, Tergaonkar, Vinay, Chng, Wee Joo, Yu, Qiang
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 28.06.2016
SeriesPNAS Plus
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-inducible factor 1, α-subunit (HIFI-α) is a crucial modulator of PRC2 and enhancer of zeste 2 (EZH2) function in breast cancer. Interrogating the genomic expression of breast cancer indicates high HIF1A activity correlated with high EZH2 expression but low PRC2 activity in triple-negative breast cancer compared with other cancer subtypes. In the absence of HIFIA activation, PRC2 represses the expression of matrix metalloproteinase genes (MMPs) and invasion, whereas a discrete Ezh2 complexed with Forkhead box M1 (FoxM1) acts to promote the expression of MMPs. HIF1-α induction upon hypoxia results in PRC2 inactivation by selective suppression of the expression of suppressor of zeste 12 protein homolog (SUZ12) and embryonic ectoderm development (EED), leading to a functional switch toward Ezh2/FoxM1-dependent induction of the expression of MMPs and invasion. Our study suggests a tumor-suppressive function of PRC2, which is restricted by HIF1-α, and an oncogenic function of Ezh2, which cooperates with FoxM1 to promote invasion in triple-negative breast cancer.
AbstractList Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-inducible factor 1, α-subunit (HIFI-α) is a crucial modulator of PRC2 and enhancer of zeste 2 (EZH2) function in breast cancer. Interrogating the genomic expression of breast cancer indicates high HIF1A activity correlated with high EZH2 expression but low PRC2 activity in triple-negative breast cancer compared with other cancer subtypes. In the absence of HIFIA activation, PRC2 represses the expression of matrix metalloproteinase genes (MMPs) and invasion, whereas a discrete Ezh2 complexed with Forkhead box M1 (FoxM1) acts to promote the expression of MMPs. HIF1-α induction upon hypoxia results in PRC2 inactivation by selective suppression of the expression of suppressor of zeste 12 protein homolog (SUZ12) and embryonic ectoderm development (EED), leading to a functional switch toward Ezh2/FoxM1-dependent induction of the expression of MMPs and invasion. Our study suggests a tumor-suppressive function of PRC2, which is restricted by HIF1-α, and an oncogenic function of Ezh2, which cooperates with FoxM1 to promote invasion in triple-negative breast cancer.
The plasticity of Polycomb repressive complex 2 (PRC2) in the context of tumorigenesis has remained a subject of contention. Here we demonstrate that the equilibrium between the oncogenic and tumor-suppressive activity of PRC2 in promoting breast cancer invasion is tightly regulated by hypoxia-inducible factor 1-α. PRC2 acts as a tumor-suppressor barrier to the hypoxia-driven invasion pathway, and the impaired PRC2 activity upon hypoxia promotes a chromatin switch at proinvasion matrix metalloproteinase gene loci. The study fundamentally changed our understanding of the role of PRC2 in breast cancer and also identified a previously unidentified function of enhancer of zeste 2 to complex with Forkhead box M1 to promote cancer invasion. Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-inducible factor 1, α-subunit (HIFI-α) is a crucial modulator of PRC2 and enhancer of zeste 2 (EZH2) function in breast cancer. Interrogating the genomic expression of breast cancer indicates high HIF1A activity correlated with high EZH2 expression but low PRC2 activity in triple-negative breast cancer compared with other cancer subtypes. In the absence of HIFIA activation, PRC2 represses the expression of matrix metalloproteinase genes ( MMP s) and invasion, whereas a discrete Ezh2 complexed with Forkhead box M1 (FoxM1) acts to promote the expression of MMP s. HIF1-α induction upon hypoxia results in PRC2 inactivation by selective suppression of the expression of suppressor of zeste 12 protein homolog ( SUZ12 ) and embryonic ectoderm development ( EED ), leading to a functional switch toward Ezh2/FoxM1-dependent induction of the expression of MMP s and invasion. Our study suggests a tumor-suppressive function of PRC2, which is restricted by HIF1-α, and an oncogenic function of Ezh2, which cooperates with FoxM1 to promote invasion in triple-negative breast cancer.
Author Mahara, Sylvia
Tergaonkar, Vinay
Chng, Wee Joo
Yu, Qiang
Lee, Puay Leng
Feng, Min
Author_xml – sequence: 1
  givenname: Sylvia
  surname: Mahara
  fullname: Mahara, Sylvia
  organization: Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Agency for Science, Technology and Research, Biopolis, Singapore 138672
– sequence: 2
  givenname: Puay Leng
  surname: Lee
  fullname: Lee, Puay Leng
  organization: Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Agency for Science, Technology and Research, Biopolis, Singapore 138672
– sequence: 3
  givenname: Min
  surname: Feng
  fullname: Feng, Min
  organization: Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Agency for Science, Technology and Research, Biopolis, Singapore 138672
– sequence: 4
  givenname: Vinay
  surname: Tergaonkar
  fullname: Tergaonkar, Vinay
  organization: SA Pathology, Adelaide, SA 5000, Australia
– sequence: 5
  givenname: Wee Joo
  surname: Chng
  fullname: Chng, Wee Joo
  organization: Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597
– sequence: 6
  givenname: Qiang
  surname: Yu
  fullname: Yu, Qiang
  organization: Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27303043$$D View this record in MEDLINE/PubMed
BookMark eNp1Uc1u1DAQtlAR3RbOnEA-ckl3bCdOfEFCq5auVAmE4Gw5zph1lbUX2yk_b8WL8Exk2ZYCEqeRZr6fmflOyFGIAQl5yuCMQSuWu2DyGZPAoVWMiQdkwUCxStYKjsgCgLdVV_P6mJzkfA0AqungETnmrQABtVgQd7m-WFc_vlNji78xxcdApzBgGj1maqibgt03zUjzZ1_shvpAywbpziQzxC_ezpMUR6TR0fNvG758-27F96A-ocmFWhMspsfkoTNjxie39ZR8uDh_v7qsrt68Xq9eXVW2Zk2pLLbOdW4-xyGX3M63KAEKhZSdHZRTQjQwoAQQqlVoOuh7aV1tZd-0VvXilLw86O6mfouDxVCSGfUu-a1JX3U0Xv89CX6jP8YbXSvBVaNmgRe3Ail-mjAXvfXZ4jiagHHKmnUALfBOsBn6_E-v3yZ3z50BzQFgU8w5odPWl18vnq39qBnofYh6H6K-D3HmLf_h3Un_n_HswLjOJab7TWTdgpSN-AlXR6nk
CitedBy_id crossref_primary_10_1172_jci_insight_157502
crossref_primary_10_1186_s40364_018_0122_2
crossref_primary_10_3389_fphar_2024_1416992
crossref_primary_10_1016_j_ajpath_2021_01_013
crossref_primary_10_1074_jbc_M117_810127
crossref_primary_10_1177_17588359241306026
crossref_primary_10_1093_lifemeta_loae017
crossref_primary_10_1111_jcmm_17450
crossref_primary_10_1111_cas_14840
crossref_primary_10_1038_s41418_024_01271_z
crossref_primary_10_1186_s12885_022_10312_0
crossref_primary_10_1158_0008_5472_CAN_20_2612
crossref_primary_10_1038_s41418_021_00836_6
crossref_primary_10_4103_JCSR_JCSR_67_19
crossref_primary_10_1038_s41388_019_1123_9
crossref_primary_10_3390_ijms22063218
crossref_primary_10_1111_cas_14905
crossref_primary_10_3390_ijms241713596
crossref_primary_10_3389_fgene_2021_658241
crossref_primary_10_3389_fcell_2021_736935
crossref_primary_10_3390_life14121645
crossref_primary_10_3892_mmr_2017_8160
crossref_primary_10_3389_fphar_2022_1115608
crossref_primary_10_1073_pnas_2201376119
crossref_primary_10_1016_j_enceco_2025_03_005
crossref_primary_10_1016_j_celrep_2018_03_013
crossref_primary_10_1172_jci_insight_166860
crossref_primary_10_1038_s41598_018_36560_4
crossref_primary_10_1172_JCI161638
crossref_primary_10_1186_s13148_023_01593_8
crossref_primary_10_3390_cancers14092121
crossref_primary_10_1007_s10142_025_01563_8
crossref_primary_10_1038_s41374_018_0104_x
crossref_primary_10_1089_genbio_2023_0020
crossref_primary_10_3389_fped_2018_00328
crossref_primary_10_1007_s11060_024_04736_w
crossref_primary_10_1042_BSR20222230
crossref_primary_10_1007_s10555_020_09905_7
crossref_primary_10_1016_j_bbagrm_2019_01_002
crossref_primary_10_1016_j_bbcan_2023_188903
crossref_primary_10_1016_j_lfs_2021_120047
crossref_primary_10_1038_s41388_024_03119_9
crossref_primary_10_1124_mol_119_117432
crossref_primary_10_3390_ijms21249501
crossref_primary_10_1080_08977194_2023_2297693
crossref_primary_10_1186_s12943_023_01786_y
crossref_primary_10_1016_j_diff_2021_08_001
crossref_primary_10_3390_ijms18061172
crossref_primary_10_1038_s41419_021_04461_6
crossref_primary_10_1016_j_biopha_2024_116624
crossref_primary_10_1002_cam4_70274
crossref_primary_10_1038_s41419_019_1935_0
crossref_primary_10_1038_s41594_019_0299_6
crossref_primary_10_1080_15384101_2016_1215699
crossref_primary_10_1038_s41388_020_01484_9
crossref_primary_10_1073_pnas_2019052118
crossref_primary_10_18632_oncotarget_20202
crossref_primary_10_1002_jcp_30992
crossref_primary_10_1016_j_semcancer_2021_03_025
crossref_primary_10_1016_j_canlet_2020_05_025
crossref_primary_10_3390_ijms24031963
crossref_primary_10_3892_ol_2019_10769
crossref_primary_10_1038_s41698_024_00691_x
crossref_primary_10_1038_s41467_022_31764_9
crossref_primary_10_1042_BSR20180268
crossref_primary_10_1002_wrna_1750
crossref_primary_10_1038_s41416_025_02961_2
crossref_primary_10_1016_j_semcancer_2023_10_005
Cites_doi 10.1002/mc.20413
10.2217/fon.13.92
10.1038/sj.emboj.7601369
10.4161/cc.8.12.8708
10.1158/1541-7786.MCR-10-0511
10.1074/jbc.272.31.19253
10.1126/science.1227604
10.1073/pnas.1933744100
10.1309/LMLIK0VIE3CJK0WD
10.18632/oncotarget.6612
10.1371/journal.pone.0005011
10.1101/gad.924501
10.1038/nature10983
10.1101/gad.181800.111
10.1038/nature11412
10.1073/pnas.0932692100
10.1016/j.molonc.2012.06.002
10.1158/0008-5472.CAN-11-3546
10.1016/j.ccell.2015.12.006
10.1038/nature10725
10.3892/ol_00000115
10.1101/gad.1524107
10.1158/0008-5472.CAN-10-4087
10.1038/nature11606
10.1038/nm.2651
10.1101/gad.1035902
10.1016/j.molcel.2005.02.015
10.1016/j.molcel.2013.08.028
10.1016/B978-0-12-407173-5.00004-2
10.1002/mc.22188
10.1016/j.biopha.2015.07.038
10.1038/nature06905
10.1038/ng.620
10.1073/pnas.191367098
10.1016/j.ccr.2013.04.008
10.1038/onc.2011.417
10.1016/j.ccr.2007.04.001
10.1002/jcb.21996
10.1073/pnas.1520032112
10.1074/jbc.M209114200
10.1038/ng.621
10.1182/blood-2012-08-450494
10.1172/JCI80325
10.1007/s10549-011-1345-1
10.1001/jama.2011.593
10.1074/jbc.M111.270843
10.1038/35021093
10.1038/onc.2008.333
10.1007/s10549-009-0572-1
10.1038/nm.3029
10.1016/j.ccr.2010.10.035
10.1073/pnas.1308953111
10.1016/j.molcel.2011.08.011
10.1371/journal.pone.0031761
10.1007/s10549-014-3089-1
10.1091/mbc.e07-04-0391
10.1101/gad.269522.115
10.1371/journal.pone.0017911
10.1093/emboj/cdg542
10.1074/jbc.M204733200
10.1101/gad.191163.112
ContentType Journal Article
Copyright Volumes 1–89 and 106–113, copyright as a collective work only; author(s) retains copyright to individual articles
Copyright_xml – notice: Volumes 1–89 and 106–113, copyright as a collective work only; author(s) retains copyright to individual articles
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1073/pnas.1602079113
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
DocumentTitleAlternate HIF1-α inhibits PRC2 to promote Ezh2/FoxM1
EISSN 1091-6490
EndPage E3744
ExternalDocumentID PMC4932959
27303043
10_1073_pnas_1602079113
26470665
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-DZ
-~X
.55
0R~
123
29P
2AX
2FS
2WC
4.4
53G
5RE
5VS
85S
AACGO
AAFWJ
AANCE
ABBHK
ABOCM
ABPLY
ABPPZ
ABTLG
ABXSQ
ABZEH
ACGOD
ACHIC
ACIWK
ACNCT
ACPRK
ADQXQ
ADULT
AENEX
AEUPB
AEXZC
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AQVQM
BKOMP
CS3
D0L
DCCCD
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HH5
HYE
IPSME
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
KQ8
L7B
LU7
N9A
N~3
O9-
OK1
PNE
PQQKQ
R.V
RHI
RNA
RNS
RPM
RXW
SA0
SJN
TAE
TN5
UKR
W8F
WH7
WOQ
WOW
X7M
XSW
Y6R
YBH
YKV
YSK
ZCA
~02
~KM
AAYXX
AFOSN
CITATION
CGR
CUY
CVF
DOOOF
ECM
EIF
JSODD
NPM
RHF
VQA
YIF
YIN
7X8
5PM
ID FETCH-LOGICAL-c415t-ce7ff8f020fe262c0919309e3668cd9f93350de6003979ea80bb6cf4c6b57c9b3
ISSN 0027-8424
IngestDate Thu Aug 21 18:04:57 EDT 2025
Fri Jul 11 08:42:37 EDT 2025
Wed Feb 19 02:39:58 EST 2025
Thu Apr 24 22:57:56 EDT 2025
Tue Jul 01 03:19:16 EDT 2025
Sun Aug 24 12:10:43 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 26
Keywords hypoxia
breast cancer
PRC2
FOXM1
EZH2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c415t-ce7ff8f020fe262c0919309e3668cd9f93350de6003979ea80bb6cf4c6b57c9b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: S.M. and Q.Y. designed research; S.M., P.L.L., and M.F. performed research; V.T. contributed new reagents/analytic tools; S.M. and W.J.C. analyzed data; Q.Y. supervised the project; and S.M. and Q.Y. wrote the paper.
Edited by Gregg L. Semenza, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved May 17, 2016 (received for review February 6, 2016)
OpenAccessLink https://www.pnas.org/content/pnas/113/26/E3735.full.pdf
PMID 27303043
PQID 1800702831
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4932959
proquest_miscellaneous_1800702831
pubmed_primary_27303043
crossref_citationtrail_10_1073_pnas_1602079113
crossref_primary_10_1073_pnas_1602079113
jstor_primary_26470665
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-06-28
PublicationDateYYYYMMDD 2016-06-28
PublicationDate_xml – month: 06
  year: 2016
  text: 2016-06-28
  day: 28
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationSeriesTitle PNAS Plus
PublicationTitle Proceedings of the National Academy of Sciences - PNAS
PublicationTitleAlternate Proc Natl Acad Sci U S A
PublicationYear 2016
Publisher National Academy of Sciences
Publisher_xml – name: National Academy of Sciences
References e_1_3_3_50_2
e_1_3_3_16_2
e_1_3_3_18_2
e_1_3_3_39_2
e_1_3_3_12_2
e_1_3_3_37_2
e_1_3_3_58_2
e_1_3_3_14_2
e_1_3_3_35_2
e_1_3_3_56_2
e_1_3_3_33_2
e_1_3_3_54_2
e_1_3_3_10_2
e_1_3_3_31_2
e_1_3_3_52_2
e_1_3_3_40_2
e_1_3_3_61_2
e_1_3_3_5_2
e_1_3_3_7_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_29_2
e_1_3_3_23_2
e_1_3_3_48_2
e_1_3_3_25_2
e_1_3_3_46_2
e_1_3_3_1_2
e_1_3_3_44_2
e_1_3_3_3_2
e_1_3_3_21_2
e_1_3_3_42_2
e_1_3_3_51_2
e_1_3_3_17_2
e_1_3_3_19_2
e_1_3_3_38_2
e_1_3_3_13_2
e_1_3_3_36_2
e_1_3_3_59_2
e_1_3_3_15_2
e_1_3_3_34_2
e_1_3_3_57_2
e_1_3_3_32_2
e_1_3_3_55_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_53_2
e_1_3_3_60_2
e_1_3_3_6_2
e_1_3_3_8_2
e_1_3_3_28_2
e_1_3_3_49_2
e_1_3_3_24_2
e_1_3_3_47_2
e_1_3_3_26_2
e_1_3_3_45_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_43_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_41_2
12052835 - J Biol Chem. 2002 Aug 16;277(33):29936-44
26517694 - J Clin Invest. 2015 Oct 26;125(12 ):4375-90
15780936 - Mol Cell. 2005 Mar 18;17(6):793-803
25224916 - Breast Cancer Res Treat. 2014 Oct;147(3):639-51
14500907 - Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
17482131 - Cancer Cell. 2007 May;11(5):407-20
23529930 - Blood. 2013 May 30;121(22):4512-20
25043748 - Mol Carcinog. 2015 Oct;54(10 ):1172-80
24156323 - Future Oncol. 2013 Nov;9(11):1623-36
18806826 - Oncogene. 2008 Dec 11;27(58):7274-84
24055345 - Mol Cell. 2013 Oct 24;52(2):193-205
21383005 - Mol Cancer Res. 2011 Apr;9(4):418-29
12379645 - J Biol Chem. 2002 Dec 13;277(50):48403-9
23239736 - Science. 2012 Dec 14;338(6113):1465-9
26766588 - Cancer Cell. 2016 Jan 11;29(1):17-31
26637281 - Genes Dev. 2015 Dec 15;29(24):2547-62
12435631 - Genes Dev. 2002 Nov 15;16(22):2893-905
18432192 - Nature. 2008 Jun 5;453(7196):807-11
23768511 - Adv Cancer Res. 2013;118:97-398
20601954 - Nat Genet. 2010 Aug;42(8):665-7
26271144 - Biomed Pharmacother. 2015 Oct;75:218-25
22508723 - Genes Dev. 2012 Apr 15;26(8):751-5
17024177 - EMBO J. 2006 Oct 18;25(20):4784-94
23684459 - Cancer Cell. 2013 Jun 10;23 (6):839-52
24516139 - Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3098-103
20601953 - Nat Genet. 2010 Aug;42(8):722-6
22766277 - Mol Oncol. 2012 Oct;6(5):494-506
14532106 - EMBO J. 2003 Oct 15;22(20):5323-35
22966359 - Oncol Lett. 2010 Jul;1(4):657-662
21445301 - PLoS One. 2011 Mar 21;6(3):e17911
22237151 - Nat Med. 2012 Feb 06;18(2):298-301
26683709 - Oncotarget. 2016 Jan 26;7(4):4584-97
21558518 - JAMA. 2011 May 11;305(18):1873-81
21225456 - Breast Cancer Res Treat. 2011 Apr;126(3):803-10
11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
23051747 - Nature. 2012 Dec 6;492(7427):108-12
18176935 - Mol Carcinog. 2008 Sep;47(9):701-6
11641274 - Genes Dev. 2001 Oct 15;15(20):2675-86
21884980 - Mol Cell. 2011 Sep 2;43(5):798-810
17437993 - Genes Dev. 2007 May 1;21(9):1050-63
22391448 - Genes Dev. 2012 Mar 1;26(5):439-44
26512116 - Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6215-23
21979956 - J Biol Chem. 2011 Dec 2;286(48):41425-33
19813088 - Breast Cancer Res Treat. 2010 Jul;122(2):337-46
21927022 - Oncogene. 2012 May 3;31(18):2283-97
17898080 - Mol Biol Cell. 2007 Dec;18(12 ):4691-7
19340297 - PLoS One. 2009;4(4):e5011
9235919 - J Biol Chem. 1997 Aug 1;272(31):19253-60
12829800 - Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
23223005 - Nat Med. 2013 Jan;19(1):50-6
21215703 - Cancer Cell. 2011 Jan 18;19(1):86-100
22237106 - Nature. 2012 Jan 11;481(7380):157-63
23000897 - Nature. 2012 Oct 4;490(7418):61-70
22505648 - Cancer Res. 2012 Jun 15;72 (12 ):3091-104
22393369 - PLoS One. 2012;7(2):e31761
21507930 - Cancer Res. 2011 Jun 15;71(12 ):4292-302
10963602 - Nature. 2000 Aug 17;406(6797):747-52
19411834 - Cell Cycle. 2009 Jun 15;8(12 ):1966-7
19097132 - J Cell Biochem. 2009 Feb 1;106(2):247-56
22522925 - Nature. 2012 Apr 18;486(7403):346-52
References_xml – ident: e_1_3_3_21_2
  doi: 10.1002/mc.20413
– ident: e_1_3_3_28_2
  doi: 10.2217/fon.13.92
– ident: e_1_3_3_35_2
  doi: 10.1038/sj.emboj.7601369
– ident: e_1_3_3_45_2
  doi: 10.4161/cc.8.12.8708
– ident: e_1_3_3_39_2
  doi: 10.1158/1541-7786.MCR-10-0511
– ident: e_1_3_3_48_2
  doi: 10.1074/jbc.272.31.19253
– ident: e_1_3_3_11_2
  doi: 10.1126/science.1227604
– ident: e_1_3_3_23_2
  doi: 10.1073/pnas.1933744100
– ident: e_1_3_3_5_2
  doi: 10.1309/LMLIK0VIE3CJK0WD
– ident: e_1_3_3_7_2
  doi: 10.18632/oncotarget.6612
– ident: e_1_3_3_40_2
  doi: 10.1371/journal.pone.0005011
– ident: e_1_3_3_49_2
  doi: 10.1101/gad.924501
– ident: e_1_3_3_24_2
  doi: 10.1038/nature10983
– ident: e_1_3_3_61_2
  doi: 10.1101/gad.181800.111
– ident: e_1_3_3_4_2
  doi: 10.1038/nature11412
– ident: e_1_3_3_3_2
  doi: 10.1073/pnas.0932692100
– ident: e_1_3_3_19_2
  doi: 10.1016/j.molonc.2012.06.002
– ident: e_1_3_3_41_2
  doi: 10.1158/0008-5472.CAN-11-3546
– ident: e_1_3_3_18_2
  doi: 10.1016/j.ccell.2015.12.006
– ident: e_1_3_3_59_2
  doi: 10.1038/nature10725
– ident: e_1_3_3_38_2
  doi: 10.3892/ol_00000115
– ident: e_1_3_3_31_2
  doi: 10.1101/gad.1524107
– ident: e_1_3_3_56_2
  doi: 10.1158/0008-5472.CAN-10-4087
– ident: e_1_3_3_46_2
  doi: 10.1038/nature11606
– ident: e_1_3_3_58_2
  doi: 10.1038/nm.2651
– ident: e_1_3_3_6_2
  doi: 10.1101/gad.1035902
– ident: e_1_3_3_36_2
  doi: 10.1016/j.molcel.2005.02.015
– ident: e_1_3_3_12_2
  doi: 10.1016/j.molcel.2013.08.028
– ident: e_1_3_3_32_2
  doi: 10.1016/B978-0-12-407173-5.00004-2
– ident: e_1_3_3_20_2
  doi: 10.1002/mc.22188
– ident: e_1_3_3_27_2
  doi: 10.1016/j.biopha.2015.07.038
– ident: e_1_3_3_51_2
  doi: 10.1038/nature06905
– ident: e_1_3_3_15_2
  doi: 10.1038/ng.620
– ident: e_1_3_3_2_2
  doi: 10.1073/pnas.191367098
– ident: e_1_3_3_9_2
  doi: 10.1016/j.ccr.2013.04.008
– ident: e_1_3_3_34_2
  doi: 10.1038/onc.2011.417
– ident: e_1_3_3_37_2
  doi: 10.1016/j.ccr.2007.04.001
– ident: e_1_3_3_26_2
  doi: 10.1002/jcb.21996
– ident: e_1_3_3_30_2
  doi: 10.1073/pnas.1520032112
– ident: e_1_3_3_53_2
  doi: 10.1074/jbc.M209114200
– ident: e_1_3_3_14_2
  doi: 10.1038/ng.621
– ident: e_1_3_3_10_2
  doi: 10.1182/blood-2012-08-450494
– ident: e_1_3_3_54_2
  doi: 10.1172/JCI80325
– ident: e_1_3_3_29_2
  doi: 10.1007/s10549-011-1345-1
– ident: e_1_3_3_47_2
  doi: 10.1001/jama.2011.593
– ident: e_1_3_3_57_2
  doi: 10.1074/jbc.M111.270843
– ident: e_1_3_3_1_2
  doi: 10.1038/35021093
– ident: e_1_3_3_42_2
  doi: 10.1038/onc.2008.333
– ident: e_1_3_3_44_2
  doi: 10.1007/s10549-009-0572-1
– ident: e_1_3_3_60_2
  doi: 10.1038/nm.3029
– ident: e_1_3_3_25_2
  doi: 10.1016/j.ccr.2010.10.035
– ident: e_1_3_3_13_2
  doi: 10.1073/pnas.1308953111
– ident: e_1_3_3_8_2
  doi: 10.1016/j.molcel.2011.08.011
– ident: e_1_3_3_55_2
  doi: 10.1371/journal.pone.0031761
– ident: e_1_3_3_22_2
  doi: 10.1007/s10549-014-3089-1
– ident: e_1_3_3_52_2
  doi: 10.1091/mbc.e07-04-0391
– ident: e_1_3_3_17_2
  doi: 10.1101/gad.269522.115
– ident: e_1_3_3_33_2
  doi: 10.1371/journal.pone.0017911
– ident: e_1_3_3_43_2
  doi: 10.1093/emboj/cdg542
– ident: e_1_3_3_50_2
  doi: 10.1074/jbc.M204733200
– ident: e_1_3_3_16_2
  doi: 10.1101/gad.191163.112
– reference: 11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
– reference: 20601954 - Nat Genet. 2010 Aug;42(8):665-7
– reference: 21927022 - Oncogene. 2012 May 3;31(18):2283-97
– reference: 25224916 - Breast Cancer Res Treat. 2014 Oct;147(3):639-51
– reference: 21979956 - J Biol Chem. 2011 Dec 2;286(48):41425-33
– reference: 21215703 - Cancer Cell. 2011 Jan 18;19(1):86-100
– reference: 22508723 - Genes Dev. 2012 Apr 15;26(8):751-5
– reference: 21383005 - Mol Cancer Res. 2011 Apr;9(4):418-29
– reference: 22966359 - Oncol Lett. 2010 Jul;1(4):657-662
– reference: 20601953 - Nat Genet. 2010 Aug;42(8):722-6
– reference: 12379645 - J Biol Chem. 2002 Dec 13;277(50):48403-9
– reference: 21445301 - PLoS One. 2011 Mar 21;6(3):e17911
– reference: 12435631 - Genes Dev. 2002 Nov 15;16(22):2893-905
– reference: 22391448 - Genes Dev. 2012 Mar 1;26(5):439-44
– reference: 22522925 - Nature. 2012 Apr 18;486(7403):346-52
– reference: 26271144 - Biomed Pharmacother. 2015 Oct;75:218-25
– reference: 26683709 - Oncotarget. 2016 Jan 26;7(4):4584-97
– reference: 22393369 - PLoS One. 2012;7(2):e31761
– reference: 22237106 - Nature. 2012 Jan 11;481(7380):157-63
– reference: 18432192 - Nature. 2008 Jun 5;453(7196):807-11
– reference: 17482131 - Cancer Cell. 2007 May;11(5):407-20
– reference: 12052835 - J Biol Chem. 2002 Aug 16;277(33):29936-44
– reference: 14532106 - EMBO J. 2003 Oct 15;22(20):5323-35
– reference: 25043748 - Mol Carcinog. 2015 Oct;54(10 ):1172-80
– reference: 10963602 - Nature. 2000 Aug 17;406(6797):747-52
– reference: 23529930 - Blood. 2013 May 30;121(22):4512-20
– reference: 15780936 - Mol Cell. 2005 Mar 18;17(6):793-803
– reference: 19340297 - PLoS One. 2009;4(4):e5011
– reference: 23223005 - Nat Med. 2013 Jan;19(1):50-6
– reference: 24055345 - Mol Cell. 2013 Oct 24;52(2):193-205
– reference: 22237151 - Nat Med. 2012 Feb 06;18(2):298-301
– reference: 22766277 - Mol Oncol. 2012 Oct;6(5):494-506
– reference: 18176935 - Mol Carcinog. 2008 Sep;47(9):701-6
– reference: 21884980 - Mol Cell. 2011 Sep 2;43(5):798-810
– reference: 18806826 - Oncogene. 2008 Dec 11;27(58):7274-84
– reference: 23684459 - Cancer Cell. 2013 Jun 10;23 (6):839-52
– reference: 23239736 - Science. 2012 Dec 14;338(6113):1465-9
– reference: 23000897 - Nature. 2012 Oct 4;490(7418):61-70
– reference: 21225456 - Breast Cancer Res Treat. 2011 Apr;126(3):803-10
– reference: 22505648 - Cancer Res. 2012 Jun 15;72 (12 ):3091-104
– reference: 26637281 - Genes Dev. 2015 Dec 15;29(24):2547-62
– reference: 19097132 - J Cell Biochem. 2009 Feb 1;106(2):247-56
– reference: 19813088 - Breast Cancer Res Treat. 2010 Jul;122(2):337-46
– reference: 26512116 - Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6215-23
– reference: 17024177 - EMBO J. 2006 Oct 18;25(20):4784-94
– reference: 21507930 - Cancer Res. 2011 Jun 15;71(12 ):4292-302
– reference: 26517694 - J Clin Invest. 2015 Oct 26;125(12 ):4375-90
– reference: 19411834 - Cell Cycle. 2009 Jun 15;8(12 ):1966-7
– reference: 17437993 - Genes Dev. 2007 May 1;21(9):1050-63
– reference: 9235919 - J Biol Chem. 1997 Aug 1;272(31):19253-60
– reference: 14500907 - Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
– reference: 21558518 - JAMA. 2011 May 11;305(18):1873-81
– reference: 26766588 - Cancer Cell. 2016 Jan 11;29(1):17-31
– reference: 12829800 - Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
– reference: 11641274 - Genes Dev. 2001 Oct 15;15(20):2675-86
– reference: 24516139 - Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3098-103
– reference: 24156323 - Future Oncol. 2013 Nov;9(11):1623-36
– reference: 23051747 - Nature. 2012 Dec 6;492(7427):108-12
– reference: 23768511 - Adv Cancer Res. 2013;118:97-398
– reference: 17898080 - Mol Biol Cell. 2007 Dec;18(12 ):4691-7
SSID ssj0009580
Score 2.4723017
Snippet Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however,...
The plasticity of Polycomb repressive complex 2 (PRC2) in the context of tumorigenesis has remained a subject of contention. Here we demonstrate that the...
SourceID pubmedcentral
proquest
pubmed
crossref
jstor
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage E3735
SubjectTerms Biological Sciences
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - physiopathology
Cell Line, Tumor
Cell Proliferation
Enhancer of Zeste Homolog 2 Protein - genetics
Enhancer of Zeste Homolog 2 Protein - metabolism
Humans
Hypoxia-Inducible Factor 1, alpha Subunit - genetics
Hypoxia-Inducible Factor 1, alpha Subunit - metabolism
PNAS Plus
Polycomb Repressive Complex 2 - genetics
Polycomb Repressive Complex 2 - metabolism
Title HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer
URI https://www.jstor.org/stable/26470665
https://www.ncbi.nlm.nih.gov/pubmed/27303043
https://www.proquest.com/docview/1800702831
https://pubmed.ncbi.nlm.nih.gov/PMC4932959
Volume 113
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLbKuOEGMWBQ_mQkJg1V2ZLYsZvLUnXqEKsqtKHdVYljbxEjndoU2B6DN-FFeCaOf_LTsUnATVQldiLl-3rO8cl3jhF6QwLFJI18jwrBPRoExEs4ZV5AlZ-CQ8uY6c5_OGHjY_r-JDrpdH60VEurMt0VVzfWlfwPqnAOcNVVsv-AbH1TOAG_AV84AsJw_CuMxwf7B972cLT9LjBNMWx61Wxtu4DYctlLetpvuXTf8lte2gSHKY9KFkk2_24wqiWGV2e6Uer04zDUw1ItWC-1Lkw4Da-LYqe111tWGoNJlVQcNCUqzm4se15vOhm0kt-6SbRJu16ef81rv-A0QdNVctn7IJ1HNVGqtUeHeSMalovTZF58turwT3nhpEAufREwLbNy5eDSmlyIWDxG7aahtU22BaqOfGHbxI4Itw1O_jD-YK30jsVFstQ5s9DnsbtNiwoXXwwXIGjT34RJ4wVrbWJ16Q66G8LSw4hFx-1Gzn2_ahHFyd61p-ne0m7-WqBjta43rWKui3Fb0c3RA3TfLUvwwHJsE3Vk8RBtVgDiHded_O0jpAzpfv3EDeFwTTic4IZw2BIO5wUGhuAW4bAmHJ4rrAm3p-mmB1m6YUu3x-h4f3Q0HHtusw5PQAxYekJypfoKXoSSIQsFoBoTP5aEsb7IYhUTEvmZZLoYnMcy6ftpyoSigqURF3FKttBGMS_kU4SFH0kVRikFB0NDxWIRMpEGWRapWFHOu2i3erMz4TrZ6w1VzmdGUcHJTKMya1Dpop16woVt4nL70C0DVT0OFgxcf57sotcVdjOwwPqzWlLI-Qom93XPLAjTgy56YrFsZjsydBFfQ7keoLu7r18p8jPT5Z3CyiqO4me33vM5utf8oV6gjXKxki8hQi7TV4ayvwFdI7mN
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIFI-%CE%B1+activation+underlies+a+functional+switch+in+the+paradoxical+role+of+Ezh2%2FPRC2+in+breast+cancer&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Mahara%2C+Sylvia&rft.au=Lee%2C+Puay+Leng&rft.au=Feng%2C+Min&rft.au=Tergaonkar%2C+Vinay&rft.date=2016-06-28&rft.eissn=1091-6490&rft.volume=113&rft.issue=26&rft.spage=E3735&rft_id=info:doi/10.1073%2Fpnas.1602079113&rft_id=info%3Apmid%2F27303043&rft.externalDocID=27303043
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8424&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8424&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8424&client=summon